Update on Trojan Trade Reps, Golden Rice, and the Search for Higher Ground
Submitted by ETC Staff on
The Golden Rice AstraZeneca saga is a case study in public science's failure to understand and address patent issues. In justifying their surrender of Vitamin A enriched GM rice to the giant corporation, the researchers claim they couldn't navigate the 70+ intellectual and tangible property conflicts that could potentially scuttle their work. There are likely no more than 11 - and possibly as few as 4, patent conflicts and one outstanding tangible property issue. A public sector group - including the people Golden Rice is intended to help - should meet to debate all the options and alternatives. The contract and the events surrounding it should be investigated.